Country: Canada
Language: English
Source: Health Canada
VANCOMYCIN (VANCOMYCIN HYDROCHLORIDE)
PHARMASCIENCE INC
J01XA01
VANCOMYCIN
500MG
POWDER FOR SOLUTION
VANCOMYCIN (VANCOMYCIN HYDROCHLORIDE) 500MG
INTRAVENOUS
10ML
Prescription
GLYCOPEPTIDES
Active ingredient group (AIG) number: 0131315003; AHFS:
APPROVED
2000-03-14
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR PMS-VANCOMYCIN Vancomycin Hydrochloride for Injection USP 0.5g and 1g Vancomycin per Vial Sterile Lyophilized Powder for Injection ANTIBIOTIC PHARMASCIENCE INC. Date of Revision: 6111 Royalmount Ave, Suite #100 March 8, 2018 Montréal, Québec H4P 2T4 www.pharmascience.com Control No. 213062 _pms-VANCOMYCIN Product Monograph _ _Page 2 of 30_ PRODUCT MONOGRAPH NAME OF DRUG PR PMS-VANCOMYCIN Vancomycin Hydrochloride for Injection USP 0.5g and 1g Vancomycin per Vial Sterile Lyophilized Powder for Injection THERAPEUTIC CLASSIFICATION Antibiotic ACTION The inhibition of cell wall synthesis has been shown by _in vitro_ studies to be responsible for the bactericidal action of vancomycin against many gram-positive bacteria. There is also evidence that RNA synthesis is selectively inhibited and the permeability of the cell membrane is altered by vancomycin. INDICATIONS AND CLINICAL USE pms-VANCOMYCIN is indicated in the therapy of severe or life-threatening staphylococcal infections in patients who cannot receive or have failed to respond to the penicillins or cephalosporins or who have infections with staphylococci resistant to other antibiotics, including methicillin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of pms- VANCOMYCIN and other antibacterial drugs, pms-VANCOMYCIN should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. In the treatment of staphylococcal endocarditis, vancomycin has been used successfully alone. In other infections due to staphylococci, including osteomyelitis, pneumonia, septicemia, and soft- tissue infections, vancomycin's effectiveness has been documented. Antibiotics are us Read the complete document